Sonoma Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
SNOA$1.14+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended | ||
|---|---|---|
| September 30, | ||
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(1,753) | $(2,902) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 74 | 90 |
| Stock-based compensation | 121 | 307 |
| Deferred income taxes | 188 | 144 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (427) | 375 |
| Inventories, net | (370) | 403 |
| Prepaid expenses and other current assets | 1,134 | 47 |
| Deferred consideration | 99 | 104 |
| Operating lease, right-of-use assets | 102 | 79 |
| Accounts payable | 219 | 132 |
| Accrued expenses and other current liabilities | 62 | (353) |
| Deferred revenue | (128) | (31) |
| Withholding tax payable | 223 | 238 |
| Operating lease liabilities | (102) | (79) |
| Net cash used in operating activities | (558) | (1,446) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (31) | (19) |
| Net cash used in investing activities | (31) | (19) |
| Cash flows from financing activities: | ||
| Proceeds (costs) from issuance of common stock, net of offering expenses | 2,289 | (5) |
| Proceeds from exercise of employee stock options | 33 | – |
| Payments for fractional shares related to reverse-split | (1) | – |
| Principal payments on short-term debt | (241) | (259) |
| Net cash provided by (used in) financing activities | 2,080 | (264) |
| Effect of exchange rate on cash and cash equivalents | (541) | 46 |
| Net increase (decrease) in cash and cash equivalents | 950 | (1,683) |
| Cash and cash equivalents, beginning of period | 3,128 | 3,820 |
| Cash and cash equivalents, end of period | $4,078 | $2,137 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $8 | $10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.